Abivax (ABVX) Projected to Release Quarterly Earnings on Monday

Abivax (NASDAQ:ABVX) is expected to issue its Q2 2026 results after the market closes on Monday, September 21st. Analysts expect Abivax to announce earnings of ($0.9170) per share and revenue of $0.7990 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Monday, September 21, 2026 at 11:40 AM ET.

Abivax Stock Performance

Shares of NASDAQ:ABVX opened at $105.04 on Friday. Abivax has a 52-week low of $69.81 and a 52-week high of $148.83. The company has a market capitalization of $9.16 billion, a P/E ratio of -20.16 and a beta of 0.96. The company has a 50-day simple moving average of $121.41 and a 200 day simple moving average of $117.69.

Wall Street Analyst Weigh In

Several analysts have issued reports on ABVX shares. Weiss Ratings restated a “sell (d-)” rating on shares of Abivax in a research note on Friday, July 17th. Morgan Stanley reissued an “overweight” rating and set a $180.00 target price on shares of Abivax in a report on Friday, July 24th. The Goldman Sachs Group assumed coverage on Abivax in a research note on Wednesday, September 9th. They issued a “buy” rating and a $155.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating on shares of Abivax in a report on Tuesday, June 30th. Finally, Truist Financial raised their price target on Abivax from $135.00 to $155.00 and gave the company a “buy” rating in a report on Thursday, July 2nd. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Abivax has an average rating of “Moderate Buy” and an average target price of $156.38.

Abivax Company Profile

Abivax is a clinical-stage biotechnology company headquartered in Paris, France, focused on developing oral therapies for chronic inflammatory and immune-mediated diseases. Its lead investigational product is obefazimod, an oral small-molecule therapy designed to enhance the production of microRNA-124, a regulator of inflammatory pathways.

Obefazimod is being developed primarily for ulcerative colitis, a chronic inflammatory disease of the colon, and has also been evaluated in Crohn’s disease.